Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
复制标题
DOI：
10.1038/tpj.2016.38
复制
发表时间：
2017-10-01
影响因子：
2.8
通讯作者：
Itoh, K.
中科院分区：
文献类型：
--
作者：
Tsuji, D.;Yokoi, M.;Itoh, K.
对5-羟色胺-3受体拮抗剂止吐治疗的抗性是一个问题。本研究评估了ABCB 1和ABCG 2多态性在先前参加随机对照试验的癌症患者中止吐治疗抵抗中的潜在作用。共156例患者进行了评价，他们的反应止吐治疗，然后再分为格拉司琼或帕洛诺司琼组。在每个治疗组中评价基因型与止吐疗效的相关性。使用多变量回归分析检查与完全缓解（CR）相关的其他风险因素。帕洛诺司琼组的基因多态性未发现显著相关性。格拉司琼组中ABCB 12677 TT和3435 TT基因型患者的CR率较高。单变量分析显示，除了ABCB 1多态性，性别和顺铂剂量与格拉司琼反应相关。多因素Logistic回归分析显示ABCB 1 3435 C>T多态性和顺铂剂量是CR的显著预测因素。
Resistance to antiemetic treatment with 5-hydroxytryptamine-3 receptor antagonist is an issue. This study evaluated the potential roles of ABCB1 and ABCG2 polymorphisms in antiemetic treatment resistance in patients with cancer previously enrolled in a randomized controlled trial. A total of 156 patients were evaluated for their responses to antiemetic therapy and then subdivided into granisetron or palonosetron groups. The genotypes were evaluated for their association with antiemetic efficacy in each treatment groups. Additional risk factors associated with complete response (CR) were examined using a multivariate regression analysis. No significant associations were identified for genetic polymorphisms in the palonosetron group. In the granisetron group, patients with ABCB1 2677TT and 3435TT genotypes had higher proportion of CR. In addition to ABCB1 polymorphisms, gender and cisplatin dose were associated with granisetron response by univariate analysis. Multivariate logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR.